Diabetes drugs known as GLP-1 agonists, like Ozempic, are riding a wave of popularity right now. But the high cost and short supply because of their popularity as a weight loss remedy are putting the drugs out of reach for those who need them. Native Americans struggle with diabetes disproportionately. Now, is there a disparity when it comes to viable treatments?
To join the discussion, call 1-800-996-2848
GUESTS
Dr. Matthew Clark, chief medical officer for the Alaska Area Native Health Service and chair of the IHS National Pharmacy and Therapeutics Committee
Tarah Nelson, post-doctoral researcher at the University of Florida
Jason Hale (Prairie Band Potawatomi), senior research scientist and director for Indigenous community engagement with the Institute for Indigenous Studies at Lehigh University
